Skip to main content
Video

Examining a New Class of Antiretroviral Therapy for Patients With Multidrug-Resistant HIV-1 Infection


September 23, 2020

php logoMax Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class investigational HIV-1 attachment inhibitor.

 

Disclosure:

The author reports no relevant financial relationships.

Reference:

Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M; BRIGHTE Trial Team. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2020 Mar 26;382(13):1232-1243. doi: 10.1056/NEJMoa1902493

Agree or disagree with an article? Share your professional thoughts on an article you read.

Your Name
12 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Back to Top